annual EBITDA:
-$261.52M-$102.47M(-64.43%)Summary
- As of today (September 16, 2025), PHAT annual EBITDA is -$261.52 million, with the most recent change of -$102.47 million (-64.43%) on December 31, 2024.
- During the last 3 years, PHAT annual EBITDA has fallen by -$124.95 million (-91.49%).
- PHAT annual EBITDA is now -20411.53% below its all-time high of -$1.27 million, reached on December 31, 2018.
Performance
PHAT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$58.12M+$17.95M(+23.59%)Summary
- As of today (September 16, 2025), PHAT quarterly EBITDA is -$58.12 million, with the most recent change of +$17.95 million (+23.59%) on June 30, 2025.
- Over the past year, PHAT quarterly EBITDA has increased by +$15.37 million (+20.91%).
- PHAT quarterly EBITDA is now -20221.68% below its all-time high of -$286.00 thousand, reached on September 30, 2018.
Performance
PHAT quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$256.75M+$15.37M(+5.65%)Summary
- As of today (September 16, 2025), PHAT TTM EBITDA is -$256.75 million, with the most recent change of +$15.37 million (+5.65%) on June 30, 2025.
- Over the past year, PHAT TTM EBITDA has dropped by -$18.43 million (-7.73%).
- PHAT TTM EBITDA is now -89674.48% below its all-time high of -$286.00 thousand, reached on September 30, 2018.
Performance
PHAT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
PHAT EBITDA Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -64.4% | +20.9% | -7.7% |
3 y3 years | -91.5% | -28.9% | -70.2% |
5 y5 years | -4.2% | -194.1% | -27.0% |
PHAT EBITDA Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -91.5% | at low | -104.3% | +23.6% | -86.1% | +5.7% |
5 y | 5-year | -110.6% | at low | -194.1% | +23.6% | -106.8% | +5.7% |
alltime | all time | <-9999.0% | at low | <-9999.0% | +40.1% | <-9999.0% | +5.7% |
PHAT EBITDA History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Jun 2025 | - | -$58.12M(-23.6%) | -$256.75M(-5.6%) |
Mar 2025 | - | -$76.07M(+36.7%) | -$272.12M(+4.1%) |
Dec 2024 | -$261.52M(+64.4%) | -$55.66M(-16.8%) | -$261.52M(-3.9%) |
Sep 2024 | - | -$66.90M(-9.0%) | -$272.21M(+14.2%) |
Jun 2024 | - | -$73.48M(+12.2%) | -$238.33M(+21.6%) |
Mar 2024 | - | -$65.47M(-1.3%) | -$196.07M(+23.3%) |
Dec 2023 | -$159.05M(-6.3%) | -$66.36M(+101.0%) | -$159.05M(+15.3%) |
Sep 2023 | - | -$33.02M(+5.7%) | -$137.97M(-5.9%) |
Jun 2023 | - | -$31.23M(+9.8%) | -$146.59M(-8.6%) |
Mar 2023 | - | -$28.45M(-37.2%) | -$160.47M(-5.5%) |
Dec 2022 | -$169.80M | -$45.28M(+8.7%) | -$169.80M(+7.9%) |
Sep 2022 | - | -$41.64M(-7.7%) | -$157.44M(+4.4%) |
Jun 2022 | - | -$45.10M(+19.4%) | -$150.84M(+7.1%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Mar 2022 | - | -$37.78M(+14.8%) | -$140.91M(+3.2%) |
Dec 2021 | -$136.57M(+10.0%) | -$32.92M(-6.1%) | -$136.57M(-12.4%) |
Sep 2021 | - | -$35.05M(-0.3%) | -$155.98M(+1.5%) |
Jun 2021 | - | -$35.16M(+5.1%) | -$153.66M(+11.1%) |
Mar 2021 | - | -$33.45M(-36.1%) | -$138.26M(+11.4%) |
Dec 2020 | -$124.16M(-50.5%) | -$52.32M(+59.8%) | -$124.16M(-26.4%) |
Sep 2020 | - | -$32.73M(+65.6%) | -$168.81M(-16.5%) |
Jun 2020 | - | -$19.76M(+2.1%) | -$202.19M(-24.9%) |
Mar 2020 | - | -$19.35M(-80.0%) | -$269.06M(+7.7%) |
Dec 2019 | -$250.95M(>+9900.0%) | -$96.96M(+46.6%) | -$249.71M(+63.0%) |
Sep 2019 | - | -$66.12M(-23.7%) | -$153.22M(+75.3%) |
Jun 2019 | - | -$86.63M(>+9900.0%) | -$87.39M(>+9900.0%) |
Dec 2018 | -$1.27M | -$479.00K(+67.5%) | -$765.00K(+167.5%) |
Sep 2018 | - | -$286.00K | -$286.00K |
FAQ
- What is Phathom Pharmaceuticals, Inc. annual EBITDA?
- What is the all time high annual EBITDA for Phathom Pharmaceuticals, Inc.?
- What is Phathom Pharmaceuticals, Inc. annual EBITDA year-on-year change?
- What is Phathom Pharmaceuticals, Inc. quarterly EBITDA?
- What is the all time high quarterly EBITDA for Phathom Pharmaceuticals, Inc.?
- What is Phathom Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
- What is Phathom Pharmaceuticals, Inc. TTM EBITDA?
- What is the all time high TTM EBITDA for Phathom Pharmaceuticals, Inc.?
- What is Phathom Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
What is Phathom Pharmaceuticals, Inc. annual EBITDA?
The current annual EBITDA of PHAT is -$261.52M
What is the all time high annual EBITDA for Phathom Pharmaceuticals, Inc.?
Phathom Pharmaceuticals, Inc. all-time high annual EBITDA is -$1.27M
What is Phathom Pharmaceuticals, Inc. annual EBITDA year-on-year change?
Over the past year, PHAT annual EBITDA has changed by -$102.47M (-64.43%)
What is Phathom Pharmaceuticals, Inc. quarterly EBITDA?
The current quarterly EBITDA of PHAT is -$58.12M
What is the all time high quarterly EBITDA for Phathom Pharmaceuticals, Inc.?
Phathom Pharmaceuticals, Inc. all-time high quarterly EBITDA is -$286.00K
What is Phathom Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
Over the past year, PHAT quarterly EBITDA has changed by +$15.37M (+20.91%)
What is Phathom Pharmaceuticals, Inc. TTM EBITDA?
The current TTM EBITDA of PHAT is -$256.75M
What is the all time high TTM EBITDA for Phathom Pharmaceuticals, Inc.?
Phathom Pharmaceuticals, Inc. all-time high TTM EBITDA is -$286.00K
What is Phathom Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
Over the past year, PHAT TTM EBITDA has changed by -$18.43M (-7.73%)